KK3A Stock Overview A late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Cytokinetics, Incorporated Competitors Price History & Performance
Summary of share price highs, lows and changes for Cytokinetics Historical stock prices Current Share Price US$46.40 52 Week High US$75.50 52 Week Low US$43.20 Beta 0.82 1 Month Change 3.57% 3 Month Change -0.85% 1 Year Change -37.30% 3 Year Change 60.00% 5 Year Change 265.35% Change since IPO 90.48%
Recent News & Updates
Cytokinetics Announces Start of AMBER-HFpEF, A Phase 2 Clinical Trial of CK-586 in Patients with Symptomatic Heart Failure with Preserved Ejection Fraction Jan 21
Cytokinetics, Incorporated Announces Start of COMET-HF, Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction Dec 03
Cytokinetics, Incorporated Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy Dec 02
Cytokinetics, Incorporated Presents Additional Data from GALACTIC-HF At the American Heart Association Scientific Sessions 2024 Nov 18
Cytokinetics, Incorporated Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy At the American Heart Association Scientific Sessions 2024 Nov 17
Cytokinetics, Incorporated Presents Additional Data from GALACTIC-HF At the American Heart Association Scientific Sessions 2024 Nov 16 See more updates
Cytokinetics Announces Start of AMBER-HFpEF, A Phase 2 Clinical Trial of CK-586 in Patients with Symptomatic Heart Failure with Preserved Ejection Fraction Jan 21
Cytokinetics, Incorporated Announces Start of COMET-HF, Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction Dec 03
Cytokinetics, Incorporated Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy Dec 02
Cytokinetics, Incorporated Presents Additional Data from GALACTIC-HF At the American Heart Association Scientific Sessions 2024 Nov 18
Cytokinetics, Incorporated Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy At the American Heart Association Scientific Sessions 2024 Nov 17
Cytokinetics, Incorporated Presents Additional Data from GALACTIC-HF At the American Heart Association Scientific Sessions 2024 Nov 16
Cytokinetics, Incorporated Announces Initiation of Phase 1 Clinical Study of CK-4015089 Nov 12
New major risk - Negative shareholders equity Nov 08
Third quarter 2024 earnings released: US$1.36 loss per share (vs US$1.35 loss in 3Q 2023) Nov 08
Cytokinetics, Incorporated to Report Q3, 2024 Results on Nov 06, 2024 Oct 24
Cytokinetics Presents Additional Data from EQUOIA-HCM At the HCMS Scientific Sessions Sep 28 Cytokinetics, Incorporated Presents Additional Data from SEQUOIA-HCM at the European Society of Cardiology Congress 2024
Second quarter 2024 earnings released: US$1.31 loss per share (vs US$1.34 loss in 2Q 2023) Aug 09
New minor risk - Share price stability Aug 08
Cytokinetics, Incorporated to Report Q2, 2024 Results on Aug 08, 2024 Jul 26
CEO, President & Director recently sold €580k worth of stock Jul 02
CEO, President & Director recently sold €1.1m worth of stock Jun 18
Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants Jun 18
New minor risk - Share price stability Jun 06
VP & Chief Accounting Officer recently sold €584k worth of stock Jun 06
New minor risk - Insider selling Jun 05 Cytokinetics, Incorporated announced that it has received $49.999992 million in funding from Royalty Pharma Development Funding, LLC May 30
Cytokinetics, Incorporated has completed a Follow-on Equity Offering in the amount of $500.000022 million.
Cytokinetics, Incorporated Announces Resignation of Sandford D. Smith as Board of Directors May 18
First quarter 2024 earnings released: US$1.33 loss per share (vs US$1.38 loss in 1Q 2023) May 09 Cytokinetics, Incorporated Announces CEDAR-HCM Is Open to Enrollment Cytokinetics, Incorporated Appoints Sung H. Lee as Executive Vice President, Effective as of May 8, 2024
Cytokinetics, Incorporated to Report Q1, 2024 Results on May 08, 2024 Apr 26
Cytokinetics, Incorporated, Annual General Meeting, May 15, 2024 Apr 09
Cytokinetics Presents Additional 48-Week Data from Forest-Hcm, the Open Label Extension Clinical Study of Aficamten, At the American College of Cardiology 73rd Annual Scientific Session Apr 05
Cytokinetics, Incorporated Provides Revenue Guidance for 2024 Feb 29
Full year 2023 earnings released: US$5.45 loss per share (vs US$4.33 loss in FY 2022) Feb 28
New major risk - Revenue and earnings growth Feb 28
Cytokinetics, Incorporated to Report Q4, 2023 Results on Feb 27, 2024 Feb 14 Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw as Chief Financial Officer, Effective February 23, 2024 Feb 04
Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw, Senior Vice President, Effective February 23, 2024 Feb 03
Novartis Pursuit of Cytokinetics Reportedly Cools Jan 12 Novartis Reportedly in Advanced Talks to Buy Cytokinetics Jan 09
Cytokinetics, Incorporated Announces Positive Results from Sequoia-Hcm, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy Dec 28
Now 20% undervalued Dec 20
Cytokinetics Presents Results from COURAGE-ALS At the 34th International Symposium on ALS/MND Dec 08
Insufficient new directors Dec 01
New minor risk - Shareholder dilution Nov 06
Third quarter 2023 earnings released: US$1.35 loss per share (vs US$1.52 loss in 3Q 2022) Nov 03
Cytokinetics, Incorporated to Report Q3, 2023 Results on Nov 02, 2023 Oct 24
Cytokinetics, Incorporated Provides Update on Cardiac Myosin Inhibitor Programs and Plans to Build a Specialty Cardiology Franchise at Virtual Investor & Analyst Day Oct 20
New minor risk - Share price stability Oct 10
Cytokinetics, Incorporated Presents Baseline Characteristics from SEQUOIA-HCM at the HCM Society Oct 08
Second quarter 2023 earnings released: US$1.34 loss per share (vs US$0.23 loss in 2Q 2022) Aug 04
Cytokinetics, Incorporated to Report Q2, 2023 Results on Aug 03, 2023 Jul 29
Cytokinetics, Incorporated Presents New Data in Patients with Non-Obstructive Hcm from Cohort 4 of Redwood-Hcm in Late-Breaking Clinical Trial Session At the European Society of Cardiology Heart Failure 2023 Congress May 24
Cytokinetics, Incorporated Announces Initiation of Phase 1 Clinical Study of CK-4021586 May 12
First quarter 2023 earnings released: US$1.38 loss per share (vs US$1.05 loss in 1Q 2022) May 05
Now 22% undervalued after recent price drop Apr 13
Now 20% undervalued after recent price drop Mar 23
Full year 2022 earnings released: US$4.33 loss per share (vs US$2.80 loss in FY 2021) Mar 03
Cytokinetics, Incorporated to Report Q4, 2022 Results on Mar 01, 2023 Feb 16
Cytokinetics, Incorporated Announces Outcome of FDA Advisory Committee Vote On Omecamtiv Mecarbil Dec 15
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3828136 Dec 08
VP & Chief Accounting Officer recently sold €83k worth of stock Nov 17
Cytokinetics, Incorporated Presents New Data at the American Heart Association Scientific Sessions 2022 Nov 08
Third quarter 2022 earnings released: US$1.52 loss per share (vs US$0.95 loss in 3Q 2021) Nov 05
Cytokinetics, Incorporated to Report Q3, 2022 Results on Nov 03, 2022 Oct 21
Cytokinetics, Incorporated Announces Continuation of COURAGE-ALS Following First Interim Analysis Oct 11
Cytokinetics, Incorporated Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HCM Society Scientific Sessions Oct 01
Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.86 loss in 2Q 2021) Aug 06
Cytokinetics and The ALS Association Announce Release of Updated PRO-ACT Database Including Data From Cytokinetics' Completed ALS Clinical Trials Aug 05
Cytokinetics, Incorporated to Report Q2, 2022 Results on Aug 04, 2022 Jul 22
Cytokinetics, Incorporated Provides Update on New Drug Application Jun 18
Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing COURAGE-ALS Jun 17
Cytokinetics, Incorporated Announces Additional Data from Redwood-HCM Presented At the American Society of Echocardiography 33Rd Annual Scientific Sessions Jun 14
First quarter 2022 earnings released: US$1.05 loss per share (vs US$0.66 loss in 1Q 2021) May 06
Cytokinetics, Incorporated to Report Q1, 2022 Results on May 04, 2022 Apr 21
Cytokinetics, Incorporated Announces Retirement of Mark A. Schlossberg as Senior Vice President, Legal, General Counsel and Secretary, Effective May 13, 2022 Apr 16 Cytokinetics, Incorporated Announces Changes to Board of Directors Cytokinetics Announces Results From METEORIC-HF and Additional Data From GALACTIC-HF Presented at the American College of Cardiology 71st Annual Scientific Session
Cytokinetics, Incorporated Announces Cohort 4 of REDWOOD-HCM is Open to Enrollment Mar 04
Cytokinetics, Incorporated Announces Cohort 4 of REDWOOD-HCM is Open to Enrollment Mar 03
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 26
Cytokinetics, Incorporated Provides Earnings Guidance for the Year 2022 Feb 25
Cytokinetics, Incorporated Announces Start of SEQUOIA-HCM, a Phase 3 Clinical Trial of Aficamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy Feb 24
Cytokinetics, Incorporated Announces Resignation of Robert M. Califf as Member of the Board of Directors Feb 17
Cytokinetics, Incorporated Announces Topline Results From METEORIC-HF Feb 16 Shareholder Returns KK3A DE Biotechs DE Market 7D 3.1% 1.0% 2.0% 1Y -37.3% -4.8% 15.2%
See full shareholder returns
Return vs Market: KK3A underperformed the German Market which returned 14.1% over the past year.
Price Volatility Is KK3A's price volatile compared to industry and market? KK3A volatility KK3A Average Weekly Movement 5.8% Biotechs Industry Average Movement 6.1% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.0% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: KK3A has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: KK3A's weekly volatility (6%) has been stable over the past year.
About the Company Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company’s drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure.
Show more Cytokinetics, Incorporated Fundamentals Summary How do Cytokinetics's earnings and revenue compare to its market cap? KK3A fundamental statistics Market cap €5.52b Earnings (TTM ) -€553.92m Revenue (TTM ) €3.09m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) KK3A income statement (TTM ) Revenue US$3.22m Cost of Revenue US$330.76m Gross Profit -US$327.54m Other Expenses US$248.87m Earnings -US$576.40m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -4.88 Gross Margin -10,175.09% Net Profit Margin -17,906.24% Debt/Equity Ratio -5,568.4%
How did KK3A perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/30 03:16 End of Day Share Price 2025/01/30 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Cytokinetics, Incorporated is covered by 37 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Carter Gould Barclays Jason Zemansky BofA Global Research Mayank Mamtani B. Riley Securities, Inc.
Show 34 more analysts 
